Neuroimaging insights into the pathophysiology of sleep disorders

Sleep

Volumn 31, Issue 6, 2008, Pages 777-794

  Desseilles, Martin ^a   Dang Vu, Thanh ^a   Schabus, Manuel ^a,b   Sterpenich, Virginie ^a   Maquet, Pierre ^a   Schwartz, Sophie ^c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF SALZBURG   (Austria)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Depression; fMRI; Insomnia; Narcolepsy; Obstructive sleep apnea syndrome; PET; REM sleep behavior disorders; Restless legs syndrome; SPECT

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CREATINE KINASE; CREATININE; FLUORODEOXYGLUCOSE F 18; GABAPENTIN; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; MODAFINIL; N ACETYLASPARTIC ACID; OPIATE AGONIST; OREXIN A; ROPINIROLE;

BRAIN BLOOD FLOW; BRAIN METABOLISM; CATAPLEXY; CEREBROSPINAL FLUID; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DOPAMINERGIC SYSTEM; ELECTROENCEPHALOGRAM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE INTAKE; HAMILTON SCALE; HUMAN; INSOMNIA; IRON METABOLISM DISORDER; LOCOMOTION; MORPHOMETRICS; MOTOR DYSFUNCTION; NARCOLEPSY; NEUROIMAGING; NEUROTRANSMISSION; NONREM SLEEP; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARASOMNIA; PARKINSON DISEASE; PERIODIC LIMB MOVEMENT; POSITIVE END EXPIRATORY PRESSURE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLOW WAVE SLEEP;

EID: 44949084828     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/31.6.777     Document Type: Review

References (156)

1. Cortoos A, Verstraeten E, Cluydts R. Neurophysiological aspects of primary insomnia: implications for its treatment. Sleep Med Rev 2006;10:255-66.
2. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111.
3. Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry 2005;66:1254-9.
4. American Academy of Sleep Medicine. International classification of sleep disorders 2nd ed: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine; 2005.
5. Bonnet MH, Arand DL. Hyperarousal and insomnia. Sleep Med Rev 1997;1:97-108.
6. Perlis ML, Merica H, Smith MT, Giles DE. Beta EEG activity and insomnia. Sleep Med Rev 2001;5:365-76.
7. Nofzinger EA, Buysse DJ, Germain A, et al. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004;161:2126-8.
8. Drummond SP, Brown GG. The effects of total sleep deprivation on cerebral responses to cognitive performance. Neuropsychopharmacology 2001;25:S68-73.
9. Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. Semin Neurol 2005;25:117-29.
10. Thomas M, Sing H, Belenky G, et al. Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity. J Sleep Res 2000;9:335-52.
11. Smith MT, Perlis ML, Chengazi VU, et al. Neuroimaging of NREM sleep in primary insomnia: a Tc-99-HMPAO single photon emission computed tomography study. Sleep 2002;25:325-35.
12. Smith MT, Perlis ML, Chengazi VU, et al. NREM sleep cerebral blood flow before and after behavior therapy for chronic primary insomnia: preliminary single photon emission computed tomography (SPECT) data. Sleep Med 2005;6:93-4.
13. Benca RM. Mood disorders. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. 4th ed: Elsevier Saunders; 2005:1311-26.
14. Schroder CM, O'Hara R. Depression and obstructive sleep apnea (OSA). Ann Gen Psychiatry 2005;4:13-20.
15. Roth T, Roehrs T, Pies R. Insomnia: pathophysiology and implications for treatment. Sleep Med Rev 2007;11:71-9.
16. Thase ME. Depression, sleep, and antidepressants. J Clin Psychiatry 1998;59 Suppl 4:55-65.
17. Gillin JC, Buchsbaum M, Wu J, et al. Sleep deprivation as a model experimental antidepressant treatment: findings from functional brain imaging. Depress Anxiety 2001;14:37-49.
18. Milak MS, Parsey RV, Keilp J, et al. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry 2005;62:397-408.
19. Clark CP, Brown GG, Archibald SL, et al. Does amygdalar perfusion correlate with antidepressant response to partial sleep deprivation in major depression? Psychiatry Res 2006;146:43-51.
20. Lustberg L, Reynolds CF. Depression and insomnia: questions of cause and effect. Sleep Med Rev 2000;4:253-62.
21. Ho AP, Gillin JC, Buchsbaum MS, et al. Brain glucose metabolism during non-rapid eye movement sleep in major depression. A positron emission tomography study. Arch Gen Psychiatry 1996;53:645-52.
22. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-7.
23. Nofzinger EA, Buysse DJ, Germain A, et al. Increased activation of anterior paralimbic and executive cortex from waking to rapid eye movement sleep in depression. Arch Gen Psychiatry 2004;61:695-702.
24. Germain A, Nofzinger EA, Kupfer DJ, Buysse DJ. Neurobiology of non-REM sleep in depression: further evidence for hypofrontality and thalamic dysregulation. Am J Psychiatry 2004;161:1856-63.
25. Buysse DJ, Tu XM, Cherry CR, et al. Pretreatment REM sleep and subjective sleep quality distinguish depressed psychotherapy remitters and nonremitters. Biol Psychiatry 1999;45:205-13.
26. Peigneux P, Laureys S, Fuchs, S, et al. Generation of rapid eye movements during paradoxical sleep in humans. Neuroimage 2001;14:701-8.
27. Wehrle R, Czisch M, Kaufmann C, et al. Rapid eye movement-related brain activation in human sleep: a functional magnetic resonance imaging study. Neuroreport 2005;16:853-7.
28. Germain A, Buysse DJ, Wood A, Nofzinger E. Functional neuroanatomical correlates of eye movements during rapid eye movement sleep in depressed patients. Psychiatry Res 2004;130:259-68.
29. Vuilleumier P, Driver J. Modulation of visual processing by attention and emotion: windows on causal interactions between human brain regions. Philos Trans R Soc Lond B Biol Sci 2007;362:837-55.
30. Braun AR, Balkin TJ, Wesensten NJ, et al. Dissociated pattern of activity in visual cortices and their projections during human rapid eye movement sleep. Science 1998;279:91-5.
31. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62.
32. Baumann CR, Bassetti CL. Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. Sleep Med Rev 2005;9:253-68
33. Plazzi G, Montagna P, Provini ,F et al. Pontine lesions in idiopathic narcolepsy. Neurology 1996;46:1250-4.
34. Bassetti C, Aldrich MS, Quint DJ. MRI findings in narcolepsy. Sleep 1997;20:630-1.
35. Frey JL, Heiserman JE. Absence of pontine lesions in narcolepsy. Neurology 1997;48:1097-9.
36. Overeem S, Steens SC, Good CD, et al. Voxel-based morphometry in hypocretin-deficient narcolepsy. Sleep 2003;26:44-6.
37. Brenneis C, Brandauer E, Frauscher B, et al. Voxel-based morphometry in narcolepsy. Sleep Med 2005;6:531-6.
38. Kaufmann C, Schuld A, Pollmacher T, Auer DP. Reduced cortical gray matter in narcolepsy: preliminary findings with voxel-based morphometry. Neurology 2002;58:1852-5.
39. Draganski B, Geisler P, Hajak G, et al. Hypothalamic gray matter changes in narcoleptic patients. Nat Med 2002;8:1186-8.
40. Buskova J, Vaneckova M, Sonka K, et al. Reduced hypothalamic gray matter in narcolepsy with cataplexy. Neuro Endocrinol Lett 2006;27:769-72.
41. Lodi R, Tonon C, Vignatelli L, et al. In vivo evidence of neuronal loss in the hypothalamus of narcoleptic patients. Neurology 2004;63:1513-15.
42. Ellis CM, Simmons A, Lemmens G, et al. Proton spectroscopy in the narcoleptic syndrome. Is there evidence of a brainstem lesion? Neurology 1998;50:S23-6.
43. Rudkin TM, Arnold DL. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol 1999;56:919-26.
44. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-7.
45. Joo EY, Tae WS, Kim JH et al. Glucose hypometabolism of hypothalamus and thalamus in narcolepsy. Ann Neurol 2004;56:437-40.
46. Joo EY, Hong SB, Tae WS, et al. Cerebral perfusion abnormality in narcolepsy with cataplexy. Neuroimage 2005;28:410-16.
47. Meyer JS, Sakai F, Karacan I et al. Sleep apnea, narcolepsy, and dreaming: regional cerebral hemodynamics. Ann Neurol 1980;7:479-85.
48. Asenbaum S, Zeithofer J, Saletu B, et al. Technetium-99m-HM-PAO SPECT imaging of cerebral blood flow during REM sleep in narcoleptics. J Nucl Med 1995;36:1150-5.
49. Ellis CM, Monk C, Simmons A, et al. Functional magnetic resonance imaging neuroactivation studies in normal subjects and subjects with the narcoleptic syndrome. Actions of modafinil. J Sleep Res 1999;8:85-93.
50. Schwartz S, Ponz A, Poryazova R, et al. Humor processing in narcoleptic patient assessed by functional MRI. Brain 2008; 131: 514-22.
51. Hong SB, Tae WS, Joo EY. Cerebral perfusion changes during cataplexy in narcolepsy patients. Neurology 2006;66:1747-9.
52. Chabas D, Habert MO, Maksud P, et al. Functional imaging of cataplexy during status cataplecticus. Sleep 2007;30:153-6.
53. Sudo Y, Suhara T, Honda Y, et al. Muscarinic cholinergic receptors in human narcolepsy: a PET study. Neurology 1998;51:1297-302.
54. Derry C, Benjamin C, Bladin P, et al. Increased serotonin receptor availability in human sleep: evidence from an [18F]MPPF PET study in narcolepsy. Neuroimage 2006;30:341-48.
55. Portas CM, Bjorvatn B, Fagerland S et al. On-line detection of extracellular levels of serotonin in dorsal raphe nucleus and frontal cortex over the sleep/wake cycle in the freely moving rat. Neuroscience 1998;83:807-14.
56. Aldrich MS, Hollingsworth Z, Penney JB. Dopamine-receptor autoradiography of human narcoleptic brain. Neurology 1992;42:410-15.
57. Kish SJ, Mamelak M, Slimovitch C, et al. Brain neurotransmitter changes in human narcolepsy. Neurology 1992;42:229-34.
58. Eisensehr I, Linke R, Tatsch K, et al. Alteration of the striatal dopaminergic system in human narcolepsy. Neurology 2003;60:1817-19.
59. MacFarlane JG, List SJ, Moldofsky H, et al. Dopamine D2 receptors quantified in vivo in human narcolepsy. Biol Psychiatry 1997;41:305-10.
60. Rinne JO, Hublin C, Partinen M et al. Positron emission tomography study of human narcolepsy: no increase in striatal dopamine D2 receptors. Neurology 1995;45:1735-8.
61. Hublin C, Launes J, Nikkinen P, Partinen M. Dopamine D2-receptors in human narcolepsy: a SPECT study with 123I-IBZM. Acta Neurol Scand 1994;90:186-9
62. Staedt J, Stoppe G, Kogler A, et al. [123I]IBZM SPET analysis of dopamine D2 receptor occupancy in narcoleptic patients in the course of treatment. Biol Psychiatry 1996;39:107-11.
63. Rinne JO, Hublin C, Nagren K, et al. Unchanged striatal dopamine transporter availability in narcolepsy: a PET study with [11C]-CFT. Acta Neurol Scand 2004;109:52-5.
64. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006;319:561-9.
65. Howard RJ, Ellis C, Bullmore ET, et al. Functional echoplanar brain imaging correlates of amphetamine administration to normal subjects and subjects with the narcoleptic syndrome. Magn Reson Imaging 1996;14:1013-6.
66. Pascual-Marqui RD, Michel CM, Lehmann D. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. Int J Psychophysiol 1994;18:49-65.
67. Saletu M, Anderer P, Semlitsch HV, et al. Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy. Psychiatry Res 2007;154:69-84.
68. Thomas RJ, Kwong K. Modafinil activates cortical and subcortical sites in the sleep-deprived state. Sleep 2006;29:1471-81.
69. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5
70. Duran J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med 2001;163:685-9.
71. Arens R, Marcus CL. Pathophysiology of upper airway obstruction: a developmental perspective. Sleep 2004;27:997-1019.
72. Mateika JH, Ellythy M. Chemoreflex control of ventilation is altered during wakefulness in humans with OSA. Respir Physiol Neurobiol 2003;138:45-57.
73. Naegele B, Thouvard V, Pepin JL, et al. Deficits of cognitive executive functions in patients with sleep apnea syndrome. Sleep 1995;18:43-52.
74. Beebe DW, Groesz L, Wells C, et al. The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data. Sleep 2003;26:298-307.
75. Alchanatis M, Zias N, Deligiorgis N, et al. Sleep apnea-related cognitive deficits and intelligence: an implication of cognitive reserve theory. J Sleep Res 2005;14:69-75.
76. Aloia MS, Arnedt JT, Davis JD, et al. Neuropsychological sequelae of obstructive sleep apnea-hypopnea syndrome: a critical review. J Int Neuropsychol Soc 2004;10:772-85.
77. Brown WD. The psychosocial aspects of obstructive sleep apnea. Semin Respir Crit Care Med 2005;26:33-43.
78. Verstraeten E, Cluydts R, Pevernagie D, Hoffmann G. Executive function in sleep apnea: controlling for attentional capacity in assessing executive attention. Sleep 2004;27:685-93
79. Macey PM, Henderson LA, Macey KE, et al. Brain morphology associated with obstructive sleep apnea. Am J Respir Crit Care Med 2002;166:1382-7.
80. Morrell MJ, McRobbie DW, Quest RA, et al. Changes in brain morphology associated with obstructive sleep apnea. Sleep Med 2003;4:451-4.
81. O'Donoghue FJ, Briellmann RS, Rochford PD et al. Cerebral structural changes in severe obstructive sleep apnea. Am J Respir Crit Care Med 2005;171:1185-90.
82. Gale SD, Hopkins RO. Effects of hypoxia on the brain: neuroimaging and neuropsychological findings following carbon monoxide poisoning and obstructive sleep apnea. J Int Neuropsychol Soc 2004;10:60-71.
83. Kamba M, Suto Y, Ohta Y, et al. Cerebral metabolism in sleep apnea. Evaluation by magnetic resonance spectroscopy. Am J Respir Crit Care Med 1997;156:296-8
84. Alchanatis M, Deligiorgis N, Zias N, et al. Frontal brain lobe impairment in obstructive sleep apnoea: a proton MR spectroscopy study. Eur Respir J 2004;24:980-6.
85. Bartlett DJ, Rae C, Thompson CH, et al. Hippocampal area metabolites relate to severity and cognitive function in obstructive sleep apnea. Sleep Med 2004;5:593-6.
86. Halbower AC, Degaonkar M, Barker PB, et al. Childhood obstructive sleep apnea associates with neuropsychological deficits and neuronal brain injury. PLoS Med 2006;3:e301.
87. Thomas RJ, Rosen BR, Stern CE, Weiss JW, Kwong KK. Functional imaging of working memory in obstructive sleep-disordered breathing. J Appl Physiol 2005;98:2236-34.
88. Ayalon L, Ancoli-Israel S, Klemfuss Z, Shalauta MD, Drummond SP. Increased brain activation during verbal learning in obstructive sleep apnea. Neuroimage 2006;31:1817-25.
89. Drummond SP, Brown GG, Gillin JC, et al. Altered brain response to verbal learning following sleep deprivation. Nature 2000;403:655-7.
90. Beebe DW, Gozal D. Obstructive sleep apnea and the prefrontal cortex: towards a comprehensive model linking nocturnal upper airway obstruction to daytime cognitive and behavioral deficits. J Sleep Res 2002;11:1-16.
91. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997;9:471-81.
92. Engleman HM, Martin SE, Deary IJ, Douglas NJ. Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome. Thorax 1997;52:114-19.
93. Harper RM, Macey PM, Henderson LA, et al. fMRI responses to cold pressor challenges in control and obstructive sleep apnea subjects. J Appl Physiol 2003;94:1583-95.
94. Henderson LA, Woo MA, Macey PM, et al. Neural responses during Valsalva maneuvers in obstructive sleep apnea syndrome. J Appl Physiol 2003;94:1063-74
95. Macey PM, Macey KE, Henderson LA, et al. Functional magnetic resonance imaging responses to expiratory loading in obstructive sleep apnea. Respir Physiol Neurobiol 2003;138:275-90.
96. Macey KE, Macey PM, Woo MA, et al. Inspiratory loading elicits aberrant fMRI signal changes in obstructive sleep apnea. Respir Physiol Neurobiol 2006;151:44-60.
97. Henderson LA, Macey KE, Macey PM, et al. Regional brain response patterns to Cheyne-Stokes breathing. Respir Physiol Neurobiol 2006;150:87-93.
98. Ficker JH, Feistel H, Moller C, et al. [Changes in regional CNS perfusion in obstructive sleep apnea syndrome: initial SPECT studies with injected nocturnal 99mTc-HMPAO]. Pneumologie 1997;51:926-30.
99. Tonon C, Vetrugno R, Lodi R, et al. Proton magnetic resonance spectroscopy study of brain metabolism in obstructive sleep apnoea syndrome before and after continuous positive airway pressure treatment. Sleep 2007;30:305-11.
100. Hashimoto K, Ono T, Honda E, et al. Effects of mandibular advancement on brain activation during inspiratory loading in healthy subjects: a functional magnetic resonance imaging study. J Appl Physiol 2006;100:579-86.
101. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.
102. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547-54
103. Pennestri MH, Whittom S, Adam B, et al. PLMS and PLMW in healthy subjects as a function of age: prevalence and interval distribution. Sleep 2006;29:1183-7.
104. Neckelmann D, Mykletun A, Dahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep 2007;30:873-80.
105. Saletu B, Anderer P, Saletu M, et al. EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med 2002;3 Suppl:S35-42.
106. Picchietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005;28:891-8.
107. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007;357:639-47.
108. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39:1000-6.
109. Etgen T, Draganski B, Ilg C, et al. Bilateral thalamic gray matter changes in patients with restless legs syndrome. Neuroimage 2005;24:1242-7.
110. Bucher SF, Seelos KC, Oertel WH, et al. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 1997;41:639-45.
111. Trenkwalder C, Bucher SF, Oertel WH, et al. Bereitschaftspotential in idiopathic and symptomatic restless legs syndrome. Electroencephalogr Clin Neurophysiol 1993;89:95-103.
112. Tergau F, Wischer S, Paulus W. Motor system excitability in patients with restless legs syndrome. Neurology 1999;52:1060-3.
113. Stiasny K, Oertel WH, Trenkwalder C. Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev 2002;6:253-65.
114. Eisensehr I, Wetter TC, Linke R et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001;57:1307-9.
115. Linke R, Eisensehr I, Wetter TC, et al. Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease? Mov Disord 2004;19:1158-62.
116. Michaud M, Soucy JP, Chabli A, et al. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002;249:164-70
117. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000;54:502-4.
118. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999;52:932-7
119. Happe S, Pirker W, Klosch G, et al. Periodic leg movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter binding. J Neurol 2003;250:83-6.
120. Tribl GG, Asenbaum S, Happe S, et al. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep. Nucl Med Commun 2004;25:55-60.
121. Staedt J, Stoppe G, Kogler A, et al. Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus). J Neural Transm Gen Sect 1993;93:71-4.
122. Staedt J, Stoppe G, Kogler A, et al. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS). J Neural Transm Gen Sect 1995;99:187-93.
123. Staedt J, Stoppe G, Kogler A, et al. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 1995;245:8-10.
124. Cervenka S, Palhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006;129:2017-28.
125. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004;5:385-91
126. Kryger MH, Roth T, Dement WC. Principles and practice of sleep medicine. Fourth ed: W.B. Saunders Company, 2005:1517.
127. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61:304-9.
128. Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001;56:263-5
129. Earley CJ, P BB, Horska A, Allen RP. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Med 2006;7:458-61.
130. Walters AS. Review of receptor agonist and antagonist studies relevant to the opiate system in restless legs syndrome. Sleep Med 2002;3:301-4.
131. Barriere G, Cazalets JR, Bioulac B, et al. The restless legs syndrome. Prog Neurobiol 2005;77:139-65.
132. von Spiczak S, Whone AL, Hammers A, et al. The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain 2005;128:906-17.
133. Sewards TV, Sewards MA. The medial pain system: neural representations of the motivational aspect of pain. Brain Res Bull 2002;59:163-80.
134. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986;9:293-308.
135. Ohayon MM. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 1997;31:333-46.
136. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996;46:388-93.
137. Gagnon JF, Bedard MA, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-9.
138. Fantini ML, Ferini-Strambi L, Montplaisir J. Idiopathic REM sleep behavior disorder: toward a better nosologic definition. Neurology 2005;64:780-6.
139. Plazzi G, Corsini R, Provini F et al. REM sleep behavior disorders in multiple system atrophy. Neurology 1997;48:1094-7.
140. Gilman S, Koeppe RA, Chervin RD, et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 2003;61:29-34.
141. Sakai K, Sastre JP, Salvert D, et al. Tegmentoreticular projections with special reference to the muscular atonia during paradoxical sleep in the cat: an HRP study. Brain Res 1979;176:233-54.
142. Culebras A, Moore JT. Magnetic resonance findings in REM sleep behavior disorder. Neurology 1989;39:1519-23.
143. Shirakawa S, Takeuchi N, Uchimura N, et al. Study of image findings in rapid eye movement sleep behavioural disorder. Psychiatry Clin Neurosci 2002;56:291-2
144. Mazza S, Soucy JP, Gravel P, et al. Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology 2006;67:1618-22.
145. Caselli RJ, Chen K, Bandy D, et al. A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior. Sleep 2006;29:927-33.
146. Miyamoto M, Miyamoto T, Kubo J, et al. Brainstem function in rapid eye movement sleep behavior disorder: the evaluation of brainstem function by proton MR spectroscopy (1H-MRS). Psychiatry Clin Neurosci 2000;54:350-1.
147. Iranzo A, Santamaria J, Pujol J et al. Brainstem proton magnetic resonance spectroscopy in idopathic REM sleep behavior disorder. Sleep 2002;25:867-70.
148. Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol 1994;241:354-71.
149. Eisensehr I, Linke R, Noachtar S, et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000;123(Pt 6):1155-60.
150. Eisensehr I, Linke R, Tatsch K, et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003;26:507-12.
151. Albin RL, Koeppe RA, Chervin RD, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000;55:1410-12.
152. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128:126-37
153. Trenkwalder C. Sleep dysfunction in Parkinson's disease. Clin Neurosci 1998;5:107-14.
154. Iranzo A, Graus F, Clover L, et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol 2006;59:178-81.
155. Bassetti C, Vella S, Donati F, et al. SPECT during sleepwalking. Lancet 2000;356:484-5.
156. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76.